A Patient-Specific Digital Twin for Adaptive Radiotherapy of Non-Small Cell Lung Cancer

TL;DR

This paper introduces COMPASS, a personalized digital twin system that uses AI to model and predict tissue toxicity in lung cancer radiotherapy, enabling adaptive treatment based on dynamic biological responses.

Contribution

The study presents a novel AI-driven digital twin architecture that models individual tissue responses over time using multi-modal imaging and dosimetry data in radiotherapy.

Findings

Early warning of toxicity risk several fractions before clinical signs

Dense BED representations reveal spatial dose textures linked to toxicity

Proof of concept for AI-guided adaptive radiotherapy

Abstract

Radiotherapy continues to become more precise and data dense, with current treatment regimens generating high frequency imaging and dosimetry streams ideally suited for AI driven temporal modeling to characterize how normal tissues evolve with time. Each fraction in biologically guided radiotherapy(BGRT) treated non small cell lung cancer (NSCLC) patients records new metabolic, anatomical, and dose information. However, clinical decision making is largely informed by static, population based NTCP models which overlook the dynamic, unique biological trajectories encoded in sequential data. We developed COMPASS (Comprehensive Personalized Assessment System) for safe radiotherapy, functioning as a temporal digital twin architecture utilizing per fraction PET, CT, dosiomics, radiomics, and cumulative biologically equivalent dose (BED) kinetics to model normal tissue biology as a dynamic time series process. A GRU autoencoder was employed to learn organ specific latent trajectories, which were classified via logistic regression to predict eventual CTCAE grade 1 or higher toxicity. Eight NSCLC patients undergoing BGRT contributed to the 99 organ fraction observations covering 24 organ trajectories (spinal cord, heart, and esophagus). Despite the small cohort, intensive temporal phenotyping allowed for comprehensive analysis of individual dose response dynamics. Our findings revealed a viable AI driven early warning window, as increasing risk ratings occurred from several fractions before clinical toxicity. The dense BED driven representation revealed biologically relevant spatial dose texture characteristics that occur before toxicity and are averaged out with traditional volume based dosimetry. COMPASS establishes a proof of concept for AI enabled adaptive radiotherapy, where treatment is guided by a continually updated digital twin that tracks each patients evolving biological response.